DSM and Amyris complete Brazilian production facility transactions
On 29 December 2017, Royal DSM and Amyris, Inc. has announced that they have closed the transaction for the sale of Amyris Brasil Ltda to DSM and the establishment of a long-term manufacturing partnership for Amyris’s high-volume products.
The consideration for Amyris Brasil Ltda (which owns and operates the Brotas 1 production facility) and intellectual property related to farnesene (a bio-based key intermediate for many applications) is USD 58 million plus an additional value share arrangement over a three-year period amounting to USD 37.5 million (aggregate upfront consideration of USD 96 million). In addition to the consideration upfront, there is potential for a future value share in line with Amyris’ business model.
According to DSM, the company will continue existing supply-agreements to Amyris and other parties. DSM will also supply Amyris with speciality compounds until it realizes its Brotas 2 specialities production facility. Amyris is accelerating the construction of its second facility dedicated to speciality products while maintaining the manufacturing process development and business support capability located in Campinas, Brazil.
Royal DSM is a global science-based company active in health, nutrition and materials. DSM delivers solutions that nourish, protect and improve performance in global markets such as food and dietary supplements, personal care, feed, medical devices, automotive, paints, electrical and electronics, life protection, alternative energy and bio-based materials.
|Amyris, Inc.is an industrial bioscience company that applies its innovative bioscience solutions to convert plant sugars into hydrocarbon molecules and produce speciality ingredients and consumer products. The company is delivering it’s No Compromise products across a number of markets, including speciality and performance chemicals, flavours and fragrances, cosmetics ingredients, pharmaceuticals, and nutraceuticals.|